Develops therapies for respiratory diseases, focusing on treatments for chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
Verona Pharma plc, headquartered in London, United Kingdom, operates as a clinical-stage biopharmaceutical company dedicated to advancing therapies for respiratory diseases with significant unmet medical needs. At the core of its innovative pipeline is ensifentrine, a promising dual inhibitor of phosphodiesterase (PDE) 3 and PDE4 enzymes delivered via inhalation. This compound acts synergistically as both a bronchodilator and an anti-inflammatory agent, currently undergoing Phase 3 clinical trials. Verona Pharma focuses on developing ensifentrine across three formulations: nebulizer, dry powder inhaler, and pressurized metered-dose inhaler, aiming to address conditions such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.
In addition to its robust clinical development program, Verona Pharma plc continues to expand its therapeutic portfolio through strategic advancements and rigorous research initiatives. The company's commitment to respiratory health underscores its mission to deliver innovative treatments that improve the quality of life for patients worldwide. With a foundation established in 2005, Verona Pharma has steadily grown its capabilities and remains dedicated to shaping the future of respiratory medicine with cutting-edge science and patient-centered innovation.
Through its headquarters in London and a global perspective, Verona Pharma plc positions itself at the forefront of biopharmaceutical innovation. By leveraging deep expertise and collaborative partnerships, the company aims to achieve regulatory milestones and bring novel therapies to market, thereby addressing critical gaps in respiratory care and enhancing outcomes for individuals living with chronic respiratory diseases.